IFF, a global leader in food ingredients and biosciences, has announced that Food Standards Australia New Zealand (FSANZ) has accepted a new heart health claim for isolated soy protein. This regulatory milestone allows food and beverage manufacturers in Australia and New Zealand to explicitly link the consumption of soy protein with the maintenance of healthy blood cholesterol levels.
The approval is the culmination of years of scientific investment and a multi-year, cross-continental research collaboration involving IFF, the Soy Nutrition Institute Global, and the U.S. Soybean Export Council (USSEC), alongside academic researchers from Australia and the University of Toronto.
What Are The Requirements for the Heart Health Claim?
Under the new FSANZ permission, manufacturers can utilise the heart health claim on packaging provided the product meets specific serving criteria. To carry the claim, the food or beverage must be formulated to help consumers achieve a daily intake of $20-25 \text{ grams}$ of isolated soy protein.
Key technical attributes of isolated soy protein cited in the submission include:
Protein Purity: A $90\%$ plant-based protein concentration.
Amino Acid Profile: A complete protein containing all nine essential amino acids.
Causal Relationship: Clinical evidence supporting a relationship between isolated soy protein intake and improved blood lipid profiles.
“The clinical evidence supports a causal relationship between isolated soy protein consumption and improved blood lipids,” said Dr. Alan Barclay, Ph.D., lead author of the FSANZ submission.
“With dyslipidemia affecting around 60% of Australian adults and many New Zealanders, daily consumption of soy protein offers a practical food-based nutrition strategy to help manage cholesterol and reduce cardiovascular risk.”
Market Impact and Portfolio Integration
For B2B stakeholders, the FSANZ ruling aligns Australia and New Zealand with 11 other major markets, including the United States, Canada, and Japan. This harmonisation allows multinational brands to streamline their health-claim messaging across the Pacific region.
IFF is positioning its SOLAE® and SUPRO® soy protein portfolios as the primary vehicles for this new claim. The functional versatility of isolated soy protein makes it a candidate for several high-growth categories:
Dairy Alternatives: Enhancing the nutritional profile of plant-based milks and yoghurts.
Beverages and Smoothies: Providing a high-protein, heart-healthy base for RTD products.
Nutrition Bars and Snacks: Offering a complete protein source that supports muscle health and cardiovascular wellness simultaneously.
Commercial Opportunity: "Clinical-to-Consumer" Bridge
Tony Andrew, Vice President of Protein Solutions for IFF Food Ingredients, emphasised that the approval validates years of rigorous research. For manufacturers, the ability to put a "clinically supported" heart health claim on a label is a powerful tool for differentiation in the increasingly crowded plant-based sector.
As consumers move away from "stealth health" and toward explicit functional benefits, the 20-25g soy protein threshold provides a clear R&D target for brands looking to capture "better-for-you" spend.
The FSANZ approval marks a significant pivot point for plant-based nutrition in the ANZ region. By providing a regulatory-backed link between a common plant protein and one of the world's most prevalent health concerns, cardiovascular disease, IFF is enabling a new generation of functional food innovation.
Industry observers expect an immediate uptick in SKU reformulations across the Australian and New Zealand grocery sectors as brands look to integrate the $20-25 \text{g}$ requirement into their "heart-healthy" product sets. This launch reinforces IFF's role as both a technical supplier and a strategic partner capable of navigating complex global regulatory landscapes to unlock value for its customers.
.png)
